AroCell AB (publ) planed to complete TPS CLIA registration in the Chinese market before the end of the year. AroCell is now expanding the collaboration in the Chinese market by including TPS CLIA on Fosun Diagnostics' fully automated system. Through this collaboration, AroCell's market coverage in the Chinese market for tumor markers is doubled.

As previously informed, AroCell's subsidiary IDL Biotech has a collaboration with ZECEN Biotech, regarding the automation of the tumor marker TPS® on all their instruments. The development project of TPS CLIA has been completed and the registration process for regulatory approval of TPS CLIA for the Chinese market continues as planned. The product is planned to be available on the Chinese market in early 2023.

The development project has been successful, and now including Fosun Diagnostics' fully automated system to further expand the market in China. The product is expected to be registered on the market during the second quarter of 2023. In total, both companies have more than 2,000 automatic CLIA systems. This is a part of AroCell's strategic plan for automation.